Clinical Trial Update: Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study

View source ↗

Summary

A completed Latin American observational study (LASSYC) examining 24-hour symptom patterns in stable COPD patients sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: AstraZeneca | Conditions: Stable COPD Patients | Status: COMPLETED